Prevalences and associated risk factors of HCV/HIV co-infection and HCV mono-infection among injecting drug users in a methadone maintenance treatment program in Taipei, Taiwan

BMC Public Health

Chung-Yeh Deng¹  Xiao-Ru Jiang⁴  Peing Chuang⁴  Lan-Huei Li⁴  Lien-Wen Su²  Muh-Yong Yen⁴  Yung-Feng Yen³ 

[1] Institute of Hospital and Health Care Administration, National Yang-Ming University, 155, Section 2, Ni-Long Street, Taipei, Taiwan;Division of Mental Health and Addiction Medicine, Taipei City Hospital, Taipei City Government, Taipei, Taiwan;Institute of Public Health, National Yang-Ming University, Taipei, Taiwan;Department of Disease Control and Prevention, Taipei City Hospital, Taipei City Government, Taipei, Taiwan

关键词: Methadone;    Injection drug use;    Taiwan;    HIV;    HCV;   

Others  :  1162742
DOI  :  10.1186/1471-2458-12-1066

 received in 2012-05-21, accepted in 2012-12-05,  发布年份 2012

【 摘 要 】

Background

Injecting drug users (IDUs) in Taiwan contributed significantly to an HIV/AIDS epidemic in 2005. In addition, studies that identified risk factors of HCV/HIV co-infection among IDUs were sparse. This study aimed to identify risk factors of HCV/HIV co-infection and HCV mono-infection, as compared with seronegativity, among injecting drug users (IDUs) at a large methadone maintenance treatment program (MMTP) in Taipei, Taiwan.

Methods

Data from enrollment interviews and HCV and HIV testing completed by IDUs upon admission to the Taipei City Hospital MMTP from 2006–2010 were included in this cross-sectional analysis. HCV and HIV testing was repeated among re-enrollees whose HCV or HIV test results were negative at the preceding enrollment. Backward stepwise multinomial logistic regression was used to identify risk factors associated with HCV/HIV co-infection and HCV mono-infection.

Results

Of the 1,447 IDUs enrolled, the prevalences of HCV/HIV co-infection, HCV mono-infection, and HIV mono-infection were 13.1%, 78.0%, and 0.4%, respectively. In backward stepwise multinomial regression analysis, after controlling for potential confounders, syringe sharing in the 6 months before MMTP enrollment was significantly positively associated with HCV/HIV co-infection (adjusted odds ratio [AOR]=27.72, 95% confidence interval [CI] 13.30–57.76). Incarceration was also significantly positively associated with HCV/HIV co-infection (AOR=2.01, 95% CI 1.71–2.37) and HCV mono-infection (AOR=1.77, 95% CI 1.52–2.06), whereas smoking amphetamine in the 6 months before MMTP enrollment was significantly inversely associated with HCV/HIV co-infection (AOR=0.44, 95% CI 0.25–0.76) and HCV mono-infection (AOR=0.49, 95% CI 0.32–0.75). HCV seroincidence was 45.25/100 person-years at risk (PYAR; 95% CI 24.74–75.92/100 PYAR) and HIV seroincidence was 0.53/100 PYAR (95% CI 0.06–1.91/100 PYAR) among re-enrolled IDUs who were HCV- or HIV-negative at the preceding enrollment.

Conclusions

IDUs enrolled in Taipei MMTPs had very high prevalences of HCV/HIV co-infection and HCV mono-infection. Interventions such as expansion of syringe exchange programs and education regarding HCV/HIV prevention should be implemented for this high-risk group of drug users.

【 授权许可】

   
2012 Yen et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, Wodak A, Panda S, Tyndall M, Toufik A, et al.: Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008, 372:1733-1745.
• [2]Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L: Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011, 378:571-583.
• [3]Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL: Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol 1997, 35:3274-3277.
• [4]Pisani E, Dadun , Sucahya PK, Kamil O, Jazan S: Sexual behavior among injection drug users in 3 indonesian cities carries a high potential for HIV spread to noninjectors. J Acquir Immune Defic Syndr 2003, 34:403-406.
• [5]Des Jarlais DC, Diaz T, Perlis T, Vlahov D, Maslow C, Latka M, Rockwell R, Edwards V, Friedman SR, Monterroso E, et al.: Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol 2003, 157:467-471.
• [6]UNAIDS: 2006 Report on the global AIDS epidemic. Geneva: joint UN programme on HIV/AIDS. 2006.
• [7]Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, et al.: Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006, 166:1632-1641.
• [8]Lewden C, Salmon D, Morlat P, Bevilacqua S, Jougla E, Bonnet F, Heripret L, Costagliola D, May T, Chene G: Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005, 34:121-130.
• [9]Kao JH, Chen PJ, Lai MY, Chen DS: Hepatitis D virus genotypes in intravenous drug users in taiwan: decreasing prevalence and lack of correlation with hepatitis B virus genotypes. J Clin Microbiol 2002, 40:3047-3049.
• [10]Chu FY, Chiang SC, Su FH, Chang YY, Cheng SH: Prevalence of human immunodeficiency virus and its association with hepatitis B, C, and D virus infections among incarcerated male substance abusers in Taiwan. J Med Virol 2009, 81:973-978.
• [11]Chang CJ, Lin CH, Lee CT, Chang SJ, Ko YC, Liu HW: Hepatitis C virus infection among short-term intravenous drug users in southern Taiwan. Eur J Epidemiol 1999, 15:597-601.
• [12]Lee TS, Shen HC, Wu WH, Huang CW, Yen MY, Wang BE, Chuang P, Shih CY, Chou YC, Liu YL: Clinical characteristics and risk behavior as a function of HIV status among heroin users enrolled in methadone treatment in northern Taiwan. Subst Abuse Treat Prev Policy 2011, 6:6. BioMed Central Full Text
• [13]Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, Sheu JC: Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007, 106:148-155.
• [14]Taiwan Centers for Disease Control and Prevention: Surveillance of HIV. Taipei, Taiwan: CDC; http://www.cdc.gov.tw/ webcite [accessed 1 Febrary 2012]. [Chinese]
• [15]Miller CL, Wood E, Spittal PM, Li K, Frankish JC, Braitstein P, Montaner JS, Schechter MT: The future face of coinfection: prevalence and incidence of HIV and hepatitis C virus coinfection among young injection drug users. J Acquir Immune Defic Syndr 2004, 36:743-749.
• [16]Tan Y, Wei QH, Chen LJ, Chan PC, Lai WS, He ML, Kung HF, Lee SS: Molecular epidemiology of HCV monoinfection and HIV/HCV coinfection in injection drug users in Liuzhou, Southern China. PLoS One 2008, 3:e3608.
• [17]Hosseini M, SeyedAlinaghi S, Kheirandish P, Esmaeli Javid G, Shirzad H, Karami N, Jahani M, Seyed Ahmadian M, Payvarmehr F, Mohraz M, et al.: Prevalence and correlates of co-infection with human immunodeficiency virus and hepatitis C virus in male injection drug users in Iran. Arch Iran Med 2010, 13:318-323.
• [18]CDC: Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. MMWR Morb Mortal Wkly Rep 2003, 52:1-16.
• [19]CfDCa P: Revised guidelines for HIV counseling, testing, and referral. MMWR Morb Mortal Wkly Rep 2001, 50:1-58.
• [20]Marc B, Bouchez-Buvry A, Wepierre JL, Boniol L, Vaquero P, Garnier M: Carbon-monoxide poisoning in young drug addicts due to indoor use of a gasoline-powered generator. J Clin Forensic Med 2001, 8:54-56.
• [21]Garfein RS, Laniado-Laborin R, Rodwell TC, Lozada R, Deiss R, Burgos JL, Cuevas-Mota J, Cerecer P, Moser K, Volker ML, et al.: Latent tuberculosis among persons at risk for infection with HIV, Tijuana, Mexico. Emerg Infect Dis 2010, 16:757-763.
• [22]Huo TI, Wu JC, Wu SI, Chang AL, Lin SK, Pan CH, Huang YH, Chang FY, Lee SD: Changing seroepidemiology of hepatitis B, C, and D virus infections in high-risk populations. J Med Virol 2004, 72:41-45.
• [23]Wu JS, Lu CF, Liu WT, Lin SY: Prevalence of antibodies to hepatitis C virus (anti-HCV) in different populations in Taiwan. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 1991, 24:55-60.
• [24]Lee HC, Ko NY, Lee NY, Chang CM, Ko WC: Seroprevalence of viral hepatitis and sexually transmitted disease among adults with recently diagnosed HIV infection in Southern Taiwan, 2000–2005: upsurge in hepatitis C virus infections among injection drug users. J Formos Med Assoc 2008, 107:404-411.
• [25]Bao YP, Liu ZM, Lu L: Review of HIV and HCV infection among drug users in China. Curr Opin Psychiatry 2010, 23:187-194.
• [26]Calzavara L, Ramuscak N, Burchell AN, Swantee C, Myers T, Ford P, Fearon M, Raymond S: Prevalence of HIV and hepatitis C virus infections among inmates of Ontario remand facilities. CMAJ 2007, 177:257-261.
• [27]Mahanta J, Borkakoty B, Das HK, Chelleng PK: The risk of HIV and HCV infections among injection drug users in northeast India. AIDS Care 2009, 21:1420-1424.
• [28]Bao YP, Liu ZM: Systematic review of HIV and HCV infection among drug users in China. Int J STD AIDS 2009, 20:399-405.
• [29]Clatts MC, Colon-Lopez V, le Giang M, Goldsamt LA: Prevalence and incidence of HCV infection among Vietnam heroin users with recent onset of injection. J Urban Health 2010, 87:278-291.
• [30]Strathdee SA, Patterson TL: Behavioral interventions for HIV-positive and HCV-positive drug users. AIDS Behav 2006, 10:115-130.
• [31]Hayashi K, Milloy MJ, Fairbairn N, Kaplan K, Suwannawong P, Lai C, Wood E, Kerr T: Incarceration experiences among a community-recruited sample of injection drug users in Bangkok, Thailand. BMC Publ Health 2009, 9:492. BioMed Central Full Text
• [32]Badiani A, Belin D, Epstein D, Calu D, Shaham Y: Opiate versus psychostimulant addiction: the differences do matter. Nat Rev Neurosci 2011, 12:685-700.
• [33]Kwiatkowski CF, Booth RE: Methadone maintenance as HIV risk reduction with street-recruited injecting drug users. J Acquir Immune Defic Syndr 2001, 26:483-489.
• [34]Terrault NA: Sexual activity as a risk factor for hepatitis C. Hepatology 2002, 36:S99-S105.